Navigation Links
QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
Date:9/24/2008

Separate survey shows high prevalence of "bothersome" vaginal atrophy symptoms among sexually active and non-sexually active postmenopausal women; results presented today at 19th Annual North American Menopause

Society Meeting

ANN ARBOR, Mich., Sept. 24 /PRNewswire/ -- Additional results of a Phase 3 study for Ophena(TM) (ospemifene tablets) for the treatment of symptoms of vulvovaginal atrophy (VVA) in postmenopausal women showed that Ophena(TM) significantly improves a broad range of clinical signs of vulvovaginal atrophy, including petechiae, pallor, friability, vaginal dryness and redness in mucosa. These are all visual observations of VVA assessed during gynecological examination and were pre-defined secondary endpoints in the study. Results were announced today by QuatRx Pharmaceuticals in a poster presentation at the 19th Annual North American Menopause Society meeting in Orlando, Florida.

Vulvovaginal atrophy is a common and progressive condition associated with menopause. Earlier this year, QuatRx announced a Phase 3 study for Ophena(TM) met all four of its co-primary endpoints. The results of the study showed statistically significant improvements in vaginal dryness and dyspareunia (painful intercourse), two of the most bothersome symptoms associated with VVA. The study also demonstrated favorable effects of Ophena(TM) on vaginal wall health as compared to placebo, measured as changes in the proportion of parabasal and superficial cells in the vaginal epithelium, as well as a favorable effect on vaginal pH levels.

The multi-center, double-blind, placebo-controlled study was conducted at 80 U.S. centers and involved 826 postmenopausal women. The additional results announced today showed that after 12 weeks of treatment, the mean scores for common clinical signs of vaginal atrophy were decreased by a statistically significant margin in the Ophena(TM) groups when compared with placebo. These pos
'/>"/>

SOURCE QuatRx Pharmaceuticals Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome
2. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
3. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
4. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
5. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
6. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
7. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
8. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
9. Memory Pharmaceuticals and Roche Expand R3487/MEM 3454 Development Program
10. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
11. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015 Egalet ... integrated specialty pharmaceutical company focused on developing, manufacturing ... closing of its previously announced underwritten public offering ... a public offering price of $11.25 per share. ... included 1,000,000 shares issued upon the exercise in ...
(Date:7/31/2015)... Calif. , July 31, 2015  Xencor, Inc. ... engineered monoclonal antibodies for the treatment of autoimmune diseases, ... appointment of Yujiro S. Hata to its ... experience in business and corporate development is a tremendous ... Ph.D., president and chief executive officer of Xencor. "Xencor ...
(Date:7/30/2015)... IRVINE, Calif. , July 30, 2015 Edwards ... the science of heart valves and hemodynamic monitoring, today announced ... company,s Board of Directors. "Bob is an ardent ... been a true privilege to have him on Edwards, board ... A. Mussallem , Edwards, chairman and CEO.  "Bob has provided ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
(Date:8/2/2015)... ... August 02, 2015 , ... ... muscles and connective tissues of a woman’s pelvic organs (uterus, bladder, and ... straining, heavy lifting, obesity, constipation, multiple vaginal deliveries, genetics, smoking, and the ...
(Date:8/1/2015)... ... 2015 , ... AlignLife Office Coordinator Heather Pugh earned the position ... patients at this natural health care center in Winamac. , "Oftentimes patients are in ... role is vital to our approach because we want to focus on the patient ...
(Date:8/1/2015)... ... 2015 , ... Western University of Health Sciences’ newest class ... growing percentage of U.S. physicians, and reflects the diversity of the communities where ... message delivered by John W. Becher, DO, president of the American Osteopathic Association, ...
(Date:8/1/2015)... (PRWEB) , ... August 01, 2015 , ... The condition ... among both men and women often causing pain and discomfort. Those who spend a ... circulatory problem, and Northeast Houston Vein Center is doing what it can to create ...
(Date:8/1/2015)... ... August 01, 2015 , ... Tina Wilcoxson, owner of Freeport ... was given that honor by the National Retail Federation, the largest retail trade association ... one of three Maine business owners to be named as such. According to the ...
Breaking Medicine News(10 mins):Health News:Minimally Invasive and Robotic Treatment for Pelvic Organ Prolapse Now Available from the Specialists at Women’s Excellence in Bladder Control 2Health News:New Patient Advocate Enhances Natural Health Care 2Health News:COMP-Northwest Welcomes Class of 2019 2Health News:COMP-Northwest Welcomes Class of 2019 3Health News:COMP-Northwest Welcomes Class of 2019 4Health News:COMP-Northwest Welcomes Class of 2019 5Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Local Retail Advocate Wins National Recognition 2
... , , Hospitals, Physicians ... , PRINCETON, N.J., Aug. 18 Twelve New Jersey ... government to test an innovative new incentive method that aims to ... The three-year trial program could serve as a basis ...
... Benefits for fighting norovirus include cost, speed, report shows ... developed a vaccine for the common viral infection norovirus ... new vaccine was "manufactured" in a tobacco plant using ... the door to faster, more inexpensive ways to bring ...
... , AUSTIN, Texas, Aug. 18 PetRel ... door-to-door pet trans p ortation services , has ... e tMD , to provide free pet travel and pet health ... will allow guests of PetMD to access PetRelocat i ...
... , ARLINGTON, Va., Aug. 18 ... Congress will add billions of dollars of un-reimbursed cost to ... patients," says K.C. McAlpin, executive director of ProEnglish, a national ... government in the United States. , , ...
... , , ... milestones achieved and immediate plans to move forward as a well ... the treatment of diabetes mellitus. Exsulin,s focus is on development of ... suffering from type 1 (T1DM) and type 2 diabetes (T2DM). ...
... , , JACKSONVILLE, Fla., ... network, today announced its partnership with Blue Cross and Blue ... and reduce the cost of care administration for Minnesotans. Blue ... the secure exchange of administrative health information between Minnesota physicians, ...
Cached Medicine News:Health News:Medicare Picks N.J. to Test Innovative Incentive System 2Health News:Medicare Picks N.J. to Test Innovative Incentive System 3Health News:Medicare Picks N.J. to Test Innovative Incentive System 4Health News:'Cruise Ship Virus' Vaccine Stems From Tobacco 2Health News:PetRelocation.com and PetMD.com Launch Co-Branded Pet Travel and Pet Health Resources 2Health News:PetRelocation.com and PetMD.com Launch Co-Branded Pet Travel and Pet Health Resources 3Health News:Exsulin Corporation Announces Publication of Phase 2 Trial Results for Novel Islet Regeneration Treatment in Type 1 & Type 2 Diabetes 2Health News:Exsulin Corporation Announces Publication of Phase 2 Trial Results for Novel Islet Regeneration Treatment in Type 1 & Type 2 Diabetes 3Health News:Exsulin Corporation Announces Publication of Phase 2 Trial Results for Novel Islet Regeneration Treatment in Type 1 & Type 2 Diabetes 4Health News:Availity Teams with Blue Cross and Blue Shield of Minnesota to Improve Health Care Efficiencies 2Health News:Availity Teams with Blue Cross and Blue Shield of Minnesota to Improve Health Care Efficiencies 3
... CO-Oximeter Control (Bayer 800 Series) is ... monitoring the performance of blood gas, ... 270 and 800 series) instrumentation. This ... Bayer 800 Rapidlab Series instruments in ...
Liquichek Blood Gas Plus CO-Oximeter Control (IL Synthesis Series) is a combination control for use in monitoring the performance of blood gas, ion-selective electrode, biosensor and CO-Oximetry anal...
Liquichek Blood Gas Plus E Control is an aqueous product used to monitor the measurement of pH, pCO2, pO2 and electrolytes. Available in four levels....
Liquichek CK/LD Isoenzyme Control features analytes used in cardiac profile testing and protein electrophoresis. Assayed for most methods including instruments, immunoinhibition kits and electrophore...
Medicine Products: